SOX2 and adenocarcinoma: In the SOX2 model, SOX2 gene gain, early stage and adenocarcinoma/SCC histology emerged as independent prognostic factors for improved survival (HRSOX2+ vs SOX2- 0.48, 95% CI: 0.28–0.83, P = 0.008; HRstage I-II vs III-IV 0.49, 95% CI: 0.37–0.65; P<0.001; HR adenocarcinoma/SCC vs other 0.67, 95% CI: 0.46-0.93; P = 0.016).